SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
SHANGHAI, March 19, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology (SGO) annual meeting on March 16, 2024. The data showed good efficacy and safety of 9MW2821 in patients with cervical cancer,...
IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies
SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 4, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced a new set of collaborations with Umoja Biopharma, Inc. ("Umoja"), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness...
People-focused Highbrook Medical Centre is Now Officially Open
AUCKLAND, New Zealand, Dec. 22, 2021 /PRNewswire/ -- Highbrook Medical Centre, the newest of Health Improvement Group's Auckland clinics, including Botany Junction and Ormiston Medical, is now officially open and accepting new patient enrolments. Despite the lockdown, Highbrook Medical Centre opened under Level 4 rules. The clinic works with employers in Highbrook Business Park and greater East Tamaki commercial areas...
AGEBOX Presents iKids-Growth: Pioneering Safe and Natural Support for Children’s Height Development
RICHMOND, VA., Aug. 11, 2025 /PRNewswire/ -- In the field of pediatric development, a significant advancement is taking shape. For years, parents have navigated a marketplace of nutritional aids—from basic multivitamins to protein powders—with little more than hope to guide them. iKids-Growth marks a meaningful step forward, moving beyond passive nutritional support and toward a more proactive, biologically-informed strategy....
Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic...
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce opening of the Investigational New Drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders...
Sino Group and Ng Teng Fong Charitable Foundation Step Up COVID Support for Children and the Elderly
HONG KONG, March 10, 2022 /PRNewswire/ -- Sino Group and its philanthropic arm, the Ng Teng Fong Charitable Foundation (NTFCF), are stepping up support for children and the elderly in combating COVID-19. The Group and NTFCF are donating 20,000 oximeters to residential care homes and elderly living alone in collaboration with its community partners, including the Hong Kong Sheng...
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin
SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant step towards commercialization by demonstrating positive safety data from the Phase 2...
The first AXA Medical Centre officially unveils
Partnering with EC Healthcare to offer one-stop health management services AXA fulfills its Payer-to Partner strategy to become customers' lifelong partner HONG KONG, Sept. 8, 2022 /PRNewswire/ -- AXA and EC Healthcare today (8 September) held the "AXA Medical Centre Unveiling and AXA Hong Kong and EC Healthcare MOU Signing Ceremony", pledging to work together to provide professional, quality,...
Chubb to Acquire Cigna’s $3 Billion Premium Revenue Personal Accident, Supplemental Health and Life Insurance Business in Seven Asia-Pacific Markets for $5.75 Billion
- Acquisition further balances Asia's share of Chubb's global portfolio – from approximately $4 billion to $7 billion in net premiums written, or approximately 20% of the company (excluding China) - Global A&H premiums grow from $3.7 billion to $6.1 billion - Asia life company premiums increase from approximately $1 billion to $4 billion...
